Unknown

Dataset Information

The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [<sup>18</sup>F]-FDOPA imaging in schizophrenia.


ABSTRACT:

Background

Current treatments for schizophrenia act directly on dopamine (DA) receptors but are ineffective for many patients, highlighting the need to develop new treatment approaches. Striatal DA dysfunction, indexed using [18F]-FDOPA imaging, is linked to the pathoetiology of schizophrenia. We evaluated the effect of a novel drug, AUT00206, a Kv3.1/3.2 potassium channel modulator, on dopaminergic function in schizophrenia and its relationship with symptom change. Additionally, we investigated the test-retest reliability of [18F]-FDOPA PET in schizophrenia to determine its potential as a biomarker for drug discovery.

Methods

Twenty patients with schizophrenia received symptom measures and [18F]-FDOPA PET scans, before and after being random

SUBMITTER: Angelescu I 

PROVIDER: S-EPMC9554157 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature